Abacus Bioscience specializes in developing immunotherapies for treating chronic infectious diseases and cancers.
Abacus Bioscience has raised $4.4M in total funding. The most recent round was Seed. The last funding was announced in February 2023.
Abacus Bioscience's investors include Seagen.
Abacus Bioscience is headquartered in Seattle, United States.
Abacus Bioscience specializes in developing immunotherapies for treating chronic infectious diseases and cancers.
Abacus Bioscience is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Abacus Bioscience — Funding & Investors." VCBacked, February 1, 2023, https://www.vcbacked.co/company/abacus-bioscience. Accessed September 30, 2026.
VCBacked. (2023). Abacus Bioscience — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/abacus-bioscience
{{cite web |title=Abacus Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/abacus-bioscience |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated